BioVentrix

About BioVentrix

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

```xml <problem> Ischemic cardiomyopathy leads to congestive heart failure due to the enlargement and impaired function of the left ventricle. Current treatments do not directly address the anatomical damage to the heart muscle, limiting their effectiveness in restoring cardiac function. </problem> <solution> BioVentrix develops surgical equipment designed to restore the size and function of the left ventricle in patients with ischemic cardiomyopathy. Their technology aims to directly address the anatomical damage caused by the disease, improving cardiac function and potentially slowing the progression of heart failure. By reshaping the left ventricle, the device helps the heart pump more efficiently, leading to improved patient outcomes. </solution> <features> - Surgical device for left ventricular restoration. - Aims to improve cardiac function in patients with ischemic cardiomyopathy. - Addresses anatomical damage to the heart muscle. </features> <target_audience> The primary target audience includes cardiac surgeons and patients suffering from heart failure due to ischemic cardiomyopathy. </target_audience> ```

What does BioVentrix do?

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

Where is BioVentrix located?

BioVentrix is based in Mansfield, United Kingdom.

When was BioVentrix founded?

BioVentrix was founded in 2003.

How much funding has BioVentrix raised?

BioVentrix has raised $48.5M.

Who founded BioVentrix?

BioVentrix was founded by David Richmond.

  • David Richmond - CEO
Location
Mansfield, United Kingdom
Founded
2003
Funding
$48.5M
Employees
18 employees
Major Investors
Andera Partners

BioVentrix

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

BioVentrix develops surgical equipment that restores the size and function of the left ventricle in patients with ischemic cardiomyopathy, a condition that leads to congestive heart failure. This technology aims to improve cardiac function and slow the progression of heart failure, addressing the anatomical damage caused by the disease.

bioventrix.com3K+
Founded 2003 – Mansfield, United Kingdom

Funding

No specific funding rounds found.

Total Funding

$48.5M

Backed by

Andera Partners

Team (15+)

David Richmond

CEO

Company Description

Problem

Ischemic cardiomyopathy leads to congestive heart failure due to the enlargement and impaired function of the left ventricle. Current treatments do not directly address the anatomical damage to the heart muscle, limiting their effectiveness in restoring cardiac function.

Solution

BioVentrix develops surgical equipment designed to restore the size and function of the left ventricle in patients with ischemic cardiomyopathy. Their technology aims to directly address the anatomical damage caused by the disease, improving cardiac function and potentially slowing the progression of heart failure. By reshaping the left ventricle, the device helps the heart pump more efficiently, leading to improved patient outcomes.

Features

Surgical device for left ventricular restoration.

Aims to improve cardiac function in patients with ischemic cardiomyopathy.

Addresses anatomical damage to the heart muscle.

Target Audience

The primary target audience includes cardiac surgeons and patients suffering from heart failure due to ischemic cardiomyopathy.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.
BioVentrix - Funding: $48.5M | StartupSeeker